Meta-Analysis of Ginseng Berry Saponin Efficacy for Heart Failure

A systematic review and meta-analysis synthesizing results from 32 randomized controlled trials involving 3,476 heart failure patients. The study, authored by Jing Wang and registered in PROSPERO (CRD420251003193), assesses the efficacy and safety of Ginseng Berry Saponin as an adjunct therapy. It was last updated on April 22, 2026.

Use Cases

• Evaluating the impact of adjunctive GBS therapy on cardiac function measures like LVEF and LVEDD
• Assessing patient-reported outcomes based on SAS, SDS, HAMA, and HAMD scores
• Analyzing the effect on inflammatory and vascular biomarkers such as CRP, TNF-α, and ET-1

Strengths

• Analysis is based on 32 randomized controlled trials
• Includes data from 3,476 patients for efficacy and safety assessment
• Uses Cochrane Risk of Bias (ROB 2.0) and GRADE methodology for quality assessment

Limitations

• The dataset is a 13.5 KB DOC file, suggesting limited raw data scope
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

Systematic literature search across seven electronic databases including PubMed and Cochrane Library.

Collection Method

Meta-analysis performed using Review Manager (RevMan, version 5.4) under a random-effects model.

Time Range

Literature search from database inception through March 31, 2025.

Freshness

Last updated 2026-04-22 05:46:58; freshness should be verified